Cerebrospinal fluid and plasma monoamines and their metabolites in euthymic bipolar patients.
In a search for trait markers in manic-depressive illness, we studied cerebrospinal fluid (CSF) and plasma monoamines and their metabolites in 25 lithium-treated euthymic bipolar patients (12 of whom provided unmedicated samples) and 30 normal volunteers. No group differences were found. Lithium treatment showed a trend to increase CSF hydroxy-indoleacetic acid (HIAA) (p = 0.05). Dopaminergic and serotonergic metabolites were highly correlated in the CSF of all three groups. We found no evidence of a trait marker for manic-depressive illness among CSF monoamines and their metabolites.
Berrettini
W H
WH
Nurnberger
J I
JI
Scheinin
M
M
Seppala
T
T
Linnoila
M
M
Narrow
W
W
Simmons-Alling
S
S
Gershon
E S
ES
D015102:3,4-Dihydroxyphenylacetic Acid / Q000134:cerebrospinal fluid; D001714:Bipolar Disorder / Q000134:cerebrospinal fluid* / Q000188:drug therapy / Q000523:psychology; D004298:Dopamine / Q000134:cerebrospinal fluid; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D008094:Lithium / Q000627:therapeutic use; D008734:Methoxyhydroxyphenylglycol / Q000134:cerebrospinal fluid; D018377:Neurotransmitter Agents / Q000134:cerebrospinal fluid*; D009638:Norepinephrine / Q000134:cerebrospinal fluid
D018377:Neurotransmitter Agents; D015102:3,4-Dihydroxyphenylacetic Acid; D008734:Methoxyhydroxyphenylglycol; D006897:Hydroxyindoleacetic Acid; D008094:Lithium; D004298:Dopamine; D009638:Norepinephrine; D006719:Homovanillic Acid